Đang chuẩn bị liên kết để tải về tài liệu:
Báo cáo khoa học: "A phase II randomized trial comparing radiotherapy with concurrent weekly cisplatin or weekly paclitaxel in patients with advanced cervical cancer"

Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học Radiation Oncology cung cấp cho các bạn kiến thức về ngành y đề tài: A phase II randomized trial comparing radiotherapy with concurrent weekly cisplatin or weekly paclitaxel in patients with advanced cervical cancer. | Geara et al. Radiation Oncology 2010 5 84 http www.ro-journal.eom content 5 1 84 RADIATION ONCOLOGY STUDY PROTOCOL Open Access A phase II randomized trial comparing radiotherapy with concurrent weekly cisplatin or weekly paclitaxel in patients with advanced cervical cancer 1 2 3 1 2 3 Fady B Geara Ali Shamseddine Ali Khalil Mirna Abboud Maya Charafeddine Muhieddine Seoud Abstract Purpose Objective This is a prospective comparison of weekly cisplatin to weekly paclitaxel as concurrent chemotherapy with standard radiotherapy for locally advanced cervical carcinoma. Materials Methods Between May 2000 and May 2004 31 women with FIGO stage IB2-IVA cervical cancer or with postsurgical pelvic recurrence were enrolled into this phase II study and randomized to receive on a weekly basis either 40 mg m2 Cisplatin group I 16 patients or 50 mg m2 paclitaxel group II 15 patients concurrently with radiotherapy. Median total dose to point A was 74 Gy range 66-92 Gy for group I and 66 Gy range 40-98 Gy for group II. Median follow-up time was 46 months. Results Patient and tumor characteristics were similar in both groups. The mean number of chemotherapy cycles was also comparable with 87 and 80 of patients receiving at least 4 doses in groups I and II respectively. Seven patients 44 of group I and 8 patients 53 of group II developed tumor recurrence. The Median Survival time was not reached for Group I and 53 months for group II. The proportion of patients surviving at 2 and 5 years was 78 and 54 for group I and 73 and 43 for group II respectively. Conclusions This small prospective study shows that weekly paclitaxel does not provide any clinical advantage over weekly cisplatin for concurrent chemoradiation for advanced carcinoma of the cervix. Introduction In many developing countries cervical cancer remains a major public health problem with high overall incidence and higher frequency of advanced stage at diagnosis. Radiation therapy remains the main treatment modality for .